Tag: PDAC

Chinese scientists achieve breakthrough in early detection of ‘king cancer’ that killed Steve Jobs

The model combines a non-contrast computed tomography (CAT) scan with an AI algorithm. In a paper published by the peer-reviewed journal Nature Medicine on Monday, the team said the specificity of the early screening model reached 99.9 per cent, implying there is only one false-positive case in every 1,000 tests….

Continue Reading Chinese scientists achieve breakthrough in early detection of ‘king cancer’ that killed Steve Jobs

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines | Journal of Translational Medicine

Personalized medicine aims to revolutionize healthcare by providing tailored treatments based on an individual’s unique characteristics. Genetic information of the host and target plays a crucial role in determining disease susceptibility and treatment response [1, 2]. By utilizing genomic analysis, biomarker identification, risk assessment, tailored treatment strategies, and continuous monitoring,…

Continue Reading Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines | Journal of Translational Medicine

COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma | BMC Gastroenterology

Bioinformatics analysis The GEO database (www.ncbi.nlm.nih.gov/geo/) provided detailed gene expression information for the GSE62165 microarray. Differentially expressed genes were identified using the online tool Morpheus (software.broadinstitute.org/morpheus/) (fold change = normal pancreatic tissue gene expression/PDAC tissue gene expression, P value < 0.05 and |log2(fold change)|>1). The downstream analysis was based on the genes with the…

Continue Reading COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma | BMC Gastroenterology

Biomedicines | Free Full-Text | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts

1. Introduction Pancreatic ductal adenocarcinoma (PDAC) has one of the highest case-specific mortality rates of all cancers [1]. Although resection remains the only curative therapy for PDAC, improvements in long-term survival are attributable to advances in systemic treatment [2,3,4,5]. Currently, 5-fluorouracil-based (i.e., with irinotecan and oxaliplatin as FOLFIRINOX) or gemcitabine-based…

Continue Reading Biomedicines | Free Full-Text | Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts

IJMS | Free Full-Text | CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

1. Introduction Recently, the morbidity and mortality rates of cancer have been increasing rapidly, posing a significant threat to human health. Cancer, a refractory and multifaceted disease, fundamentally originates from a cumulative series of mutations in the cellular genome and epigenome. These mutations activate oncogenes and deactivate tumor suppressors, leading…

Continue Reading IJMS | Free Full-Text | CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Updated plan follows PanCAN’s strategic re-evaluation of the Precision PromiseSM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as planned New Phase 3 strategy provides significant value-creation opportunities SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics)…

Continue Reading Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Unveiling the transcriptomic and epigenetic secrets across 11 tumors

In a recent study published in Nature, researchers created a pan-tumor transcriptomic and epigenetic atlas using single-nucleus chromatin accessibility information and matched ribonucleic acid (RNA)-sequencing data. Study: Epigenetic regulation during cancer transitions across 11 tumour types. Image Credit: ART-ur/Shutterstock.com The researchers studied the spatiotemporal dynamics of chromatin decondensation and transcriptional…

Continue Reading Unveiling the transcriptomic and epigenetic secrets across 11 tumors

What is the role of SMAD4 gene in pancreatic cancer?

The role of the SMAD4 gene in pancreatic cancer is not mentioned in the provided text information. The role of SMAD4 gene in pancreatic cancer is still controversial, but it is associated with worse overall survival and metastasis. The role of the SMAD4 gene in pancreatic cancer is discussed in…

Continue Reading What is the role of SMAD4 gene in pancreatic cancer?

Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

Patients This clinical trial was conducted at 16 academic hospitals in Korea, from November 2015 through April 2020. A total of 511 patients underwent a screening test after providing written informed consent (Fig. 1). During the screening, every patient was checked for their serum eotaxin level, where 174 (34.1%) of them…

Continue Reading Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment | APL Bioengineering

Stimuli-sensitive drug delivery system (DDS) has attracted tremendous attention due to its ability to allow drug release through a controlled manner in response to endogenous or exogenous stimuli, which can exert site-specific therapeutic effect while minimizing the side effects.1 Extensive efforts have been devoted to explore the ideal DDS capable…

Continue Reading Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment | APL Bioengineering

Discovery of a novel therapeutic target for pancreatic cancer

A recent Scientific Reports study identified a novel amino acid transporter-based therapeutic target for pancreatic ductal adenocarcinoma (PDAC). Study: Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer. Image Credit: mi_viri/Shutterstock.com Background PDAC cells have an elevated proliferation capacity and are in significant demand for nutrients, i.e.,…

Continue Reading Discovery of a novel therapeutic target for pancreatic cancer

Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects | Biomarker Research

The exploration of methylated biomarkers in plasma for pancreatic cancer is still in its early stages, and the number of studies conducted to date for this purpose is limited. Analysis of cfDNA methylation patterns in pancreatic cancer has been approached both at the whole genome level and by identifying and…

Continue Reading Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects | Biomarker Research

ncRNA | Free Full-Text | The Intergenic Type lncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision

CRC Upregulated 153-5p HIF-1 activates LINC00511, targeting HIF-1’s 3-UTR and +ve feedback loop [78] Oncogene Human CRC tissues vs. paired adjacent non-tumor and CRC cell lines HT29, LOVO, SW620, SW480 vs. normal colon epithelial FHC cell line and athymic BALB/c nude mice for implantation – HNF4 promotes LINC00511 transcription, interaction…

Continue Reading ncRNA | Free Full-Text | The Intergenic Type lncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma | Cancer Research

As circRNAs act as miRNA sponges to regulate downstream genes expression (34), we conducted mRNA transcriptome analysis in PANC-1 cells to identify the targets of circARFGEF2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the JAK–STAT pathway was the most significantly enriched pathway associated with circARFGEF2 (Fig….

Continue Reading Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma | Cancer Research

A Novel Therapeutic Target Identified for Pancreatic Ductal Adenocarcinoma

Researchers have identified a novel therapeutic target for pancreatic ductal adenocarcinoma (PDAC), a lethal type of pancreatic cancer. Pancreatic cancer is responsible for over 90% of all cases. Previous studies have not been able to identify the master regulator of cell cycle entry and proliferative metabolism in PDAC. The researchers…

Continue Reading A Novel Therapeutic Target Identified for Pancreatic Ductal Adenocarcinoma

Role of Super-Enhancers in Triggering Pancreatic Cancer Tumor Growth Explored in Study

NEW YORK — Researchers have identified how gene regulatory regions called super-enhancers can fuel the growth of pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90 percent of all pancreatic cancer cases. In a study published in Nature Communications on Wednesday, a team led by researchers from the Salk Institute…

Continue Reading Role of Super-Enhancers in Triggering Pancreatic Cancer Tumor Growth Explored in Study

“Mouse Modeling of Pancreatic Ductal Adenocarcinoma (PDAC); Search for ” by Kyoko Kojima

Degree Name by School School of Medicine [MED]; Doctor of Philosophy (PhD) Abstract PDAC is a highly malignant neoplasm that carries a very poor prognosis. PDAC development is a multistage transformation process that involves multiple genetic alterations that include activation of EGFR/HER2 and KRAS, and loss-of-function mutations in INK4A/ARF, p53…

Continue Reading “Mouse Modeling of Pancreatic Ductal Adenocarcinoma (PDAC); Search for ” by Kyoko Kojima

FDA Grants Breakthrough Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer

The FDA has a granted breakthrough therapy designation to zenocutuzumab (MCLA-128) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion-positive pancreatic cancer following disease progression on previous systemic therapy or for whom there are no satisfactory alternative options available.1 Findings from an early access program (EAP) assessing…

Continue Reading FDA Grants Breakthrough Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer

Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation

doi: 10.1021/acsnano.3c05009. Online ahead of print. Xin Long  1 , Anna Dai  2 , Teng Huang  2 , Wenhao Niu  3 , Luoxia Liu  4 , Hui Xu  5 , Tao Yin  6 , Tian’an Jiang  7 , Shuguo Sun  2 , Ping Lei  3 , Chun Li  8 , Xiaohua Zhu  4 , Jun Zhao  2   4   9 Affiliations…

Continue Reading Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation

NALIRIFOX Delivers Substantial Survival Advantage to Patients With mPDAC

Statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) has been achieved with liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU) and oxaliplatin (NALIRIFOX) over gemcitabine plus nab-paclitaxel in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC), results from the phase 3 NAPOLI 3 study (NCT04083235) show.1…

Continue Reading NALIRIFOX Delivers Substantial Survival Advantage to Patients With mPDAC

New Products Posted to GenomeWeb: LabCorp, BostonGene, Seer, Myriad Genetics, More

Laboratory Corporation of America Plasma Focus Labcorp has launched its Plasma Focus liquid biopsy test, which analyzes cell-free DNA to enable targeted therapy selection for patients with advanced or metastatic solid tumors. The test in intended for use in patients with non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, and…

Continue Reading New Products Posted to GenomeWeb: LabCorp, BostonGene, Seer, Myriad Genetics, More

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)  Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch  Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and…

Continue Reading BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Screening/validation of pivotal pancreatic cancer gene DPYD

Introduction Pancreatic cancer (PC) is a malignant tumor with a very high mortality rate for which there is no effective treatment other than surgery.1,2 PC is prone to metastasis and invasion in the early stage, and there is no effective means for early detection. Most patients often have cancer metastasis…

Continue Reading Screening/validation of pivotal pancreatic cancer gene DPYD

NANOBIOTIX Provides First Quarter 2023 Operational and

PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the for the…

Continue Reading NANOBIOTIX Provides First Quarter 2023 Operational and

Personalized mRNA vaccine could aid in the fight against pancreatic cancer

Scientists have created the first-of-its-kind personalized mRNA vaccine in an effort to combat pancreatic cancer.  Patients were enrolled in clinical trials to test this personalized approach to treat a type of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC).  The approach to creating a cancer vaccine  Recent studies have found…

Continue Reading Personalized mRNA vaccine could aid in the fight against pancreatic cancer

Cell therapy data shows killing of pancreatic cancer tumoroids

LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids.  The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel),…

Continue Reading Cell therapy data shows killing of pancreatic cancer tumoroids

Biomea Fusion Reports First Quarter 2023 Financial Results

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes Continued enrolling four liquid tumor cohorts in ongoing Phase I…

Continue Reading Biomea Fusion Reports First Quarter 2023 Financial Results

A one-pot isothermal Cas12-based assay for the sensitive detection of microRNAs

Mechanistic studies of the EXTRA-CRISPR assay The assay is designed to be a tri-enzymatic cascade that exploits the unique nucleolytic cleavage activities of the CRISPR–Cas12a system to create a new exponential isothermal amplification mechanism based on the robust linear RCA assay. The assay starts with the hybridization of a padlock…

Continue Reading A one-pot isothermal Cas12-based assay for the sensitive detection of microRNAs

Comprehensive DNA methylation analysis indicates that pancreatic intraepithelial neoplasia lesions are acinar-derived and epigenetically primed for carcinogenesis | Cancer Research

Pancreatic ductal adenocarcinoma (PDAC) is believed to arise from the accumulation of a series of somatic mutations and is also frequently associated with pancreatic intraepithelial neoplasia (PanIN) lesions. However, there is still debate as to whether the cell-type-of-origin of PanINs and PDACs in humans is acinar or ductal. As cell…

Continue Reading Comprehensive DNA methylation analysis indicates that pancreatic intraepithelial neoplasia lesions are acinar-derived and epigenetically primed for carcinogenesis | Cancer Research

JCI – POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling

ResearchIn-Press PreviewCell biology Open Access | 10.1172/JCI165934 Grace Oh,1 Annie Wang,2 Lidong Wang,2 Jiufeng Li,2 Gregor Werba,1 Daniel Weissinger,1 Ende Zhao,2 Surajit Dhara,2 Rosmel E. Hernandez,2 Amanda Ackermann,2 Sarina Porcella,3 Despoina Kalfakakou,2 Igor Dolgalev,4 Emily A. Kawaler,2 Talia Golan,5 Theodore H. Welling,1 Agnel Sfeir,3 and Diane M. Simeone1 1Department of…

Continue Reading JCI – POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling

Biomea Fusion Reports Fourth Quarter and Full Year 2022

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphocytic and…

Continue Reading Biomea Fusion Reports Fourth Quarter and Full Year 2022

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

This protocol will allow researchers to not only streamline their analysis pipeline, but it will also allow them to extract more information out of their organoid stream, thereby enhancing the translational relevance. The main advantage of this protocol is it combines a streamlined workflow with an automated and clinically relevant…

Continue Reading Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Role of imaging in the applicability of irreversible electroporation for the management of pancreatic adenocarcinoma

. 2023 Jan-Feb;56(1):42-49. doi: 10.1590/0100-3984.2022.0032-en. Affiliations Expand Affiliation 1 Hospital Vila Nova Star, Rede D’Or, São Paulo, SP, Brazil. Item in Clipboard Thiago Pereira Fernandes da Silva et al. Radiol Bras. 2023 Jan-Feb. Show details Display options Display options Format AbstractPubMedPMID . 2023 Jan-Feb;56(1):42-49. doi: 10.1590/0100-3984.2022.0032-en. Affiliation 1 Hospital Vila Nova…

Continue Reading Role of imaging in the applicability of irreversible electroporation for the management of pancreatic adenocarcinoma

Purple Biotech sees positive results from cancer study

Purple Biotech Ltd. has released new results from exploratory analyses conducted as part of a phase 1 dose escalation study that assessed the safety and tolerability of nivolumab and CM24, which is a monoclonal antibody.  Purple Biotech is a clinical-stage company developing first-in-class therapies that harness the tumor microenvironment (TME)…

Continue Reading Purple Biotech sees positive results from cancer study

Novobiocin attacks BRCA-mutated cancer cells from within and without, study shows

Efficacy of POLθ inhibition in HR-deficient cancers requires CD8+ T cells. a, b K14-Cre-Brca1f/f;Trp53f/f TNBC tumors from syngeneic FVB/129P2 mice (VEH, n = 5; NVB, n = 7) (a), or Brca2 KO KPC PDAC tumors from syngeneic C57BL/6 mice (VEH, n = 7; NVB, n = 6) (b) were subjected to IHC for CD3, CD4, and CD8 expression….

Continue Reading Novobiocin attacks BRCA-mutated cancer cells from within and without, study shows

Dr. Wainberg on the Rationale For the Phase 3 NAPOLI 3 Trial in Patients With PDAC

Zev A. Wainberg, MD, professor of medicine, University of California, Los Angeles (UCLA), co-director, the UCLA GI Oncology Program, discusses the rationale behind the phase 3 NAPOLI 3 trial (NCT04083235) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The NAPOLI 3 trial evaluated liposomal irinotecan (Onivyde) plus 5-fluorouracil (5-FU), leucovorin,…

Continue Reading Dr. Wainberg on the Rationale For the Phase 3 NAPOLI 3 Trial in Patients With PDAC

Protein Partnership Curbs Growth of Pancreatic Cancer

Register for FREE to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. Scientists at VCU Massey Cancer Center uncovered a previously…

Continue Reading Protein Partnership Curbs Growth of Pancreatic Cancer

Protein partnership effectively fends off pancreatic cancer progression

Model for the functional interaction between Smad4 and Prdm16 during PDAC formation and progression. Credit: Journal of Cell Biology (2023). DOI: 10.1083/jcb.202203036 Scientists at VCU Massey Cancer Center have uncovered a previously unrecognized relationship between two sets of proteins that operate in tandem to fend off the growth of pancreatic…

Continue Reading Protein partnership effectively fends off pancreatic cancer progression

Crosstalk between cGAS-STING pathway and autophagy in cancer immunity

1 Introduction Cancer is one of the world’s most serious threats to human health, with high morbidity and mortality rates, and according to the latest global data, 9.96 million patients will die from cancer in 2020 (1). Cancer is a genetic abnormal disease triggered by a long-term combination of multiple…

Continue Reading Crosstalk between cGAS-STING pathway and autophagy in cancer immunity

m6A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m6A/PD-L1 manner

Emerging evidence indicates the critical roles of N6-methyladenosine (m6A) modification in human cancers. Herein, our work reported that a novel m6A-modified circRNA from the MYO1C gene, circMYO1C, upregulated in the pancreatic ductal adenocarcinoma (PDAC). Our findings demonstrated that circMYO1C is highly expressed in PDAC tissues. Functionally, circMYO1C promoted the proliferation…

Continue Reading m6A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m6A/PD-L1 manner

Bridging biological cfDNA features and machine learning approaches: Trends in Genetics

Early detection (pancreatic cancer) cfMeDIP-seq, 5hmC sequencing LR elastic-net Hierarchical clustering, t-SNE, LR with elastic-net penalization Methylation (5mC-5hmC) 208 (72/136) 24-feature 5mC, 27-features 5hmC, 51-features combined model SML, UML Combined 5mC and 5hmC AUC of 0.997 (sensitivity 0.938, specificity 0.955) Median total reads: 17.4 M, 0.8 nonduplicate mapping rate pms.cd120.com/PDAC/index.html…

Continue Reading Bridging biological cfDNA features and machine learning approaches: Trends in Genetics

Functionalizing the genome to find novel pancreatic cancer treatments

Taped outside of the lab of Dr. Christopher Kemp, a professor in the Human Biology Division, hangs a piece of paper with an earlier version of the Fred Hutch logo- a DNA helix integrated between an “H” with the slogan, “Advancing Knowledge, Saving Lives”. Russell Moser, a research scientist in…

Continue Reading Functionalizing the genome to find novel pancreatic cancer treatments

Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in Panc-1 cells – Hou

Introduction Pancreatic cancer (PC) is one of the most aggressive and lethal cancers (1). Previous studies have shown that aging, environmental and behavioral changes are more closely related to the dramatic increase in the incidence of PC worldwide than genetic factors (2–5). A position paper published by the European Federation…

Continue Reading Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in Panc-1 cells – Hou

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

IRE combined with toripalimab versus IRE alone for LAPC

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…

Continue Reading IRE combined with toripalimab versus IRE alone for LAPC

Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing

Possible biomarkers for prognosis and clinical outcomes were identified, through the use whole exome sequencing and RNA sequencing, as therapeutic targets for patients with pancreatic ductal adenocarcinoma (PDAC), according to a recent study. The study, published in Therapeutic Advances in Medical Oncology, also reconfirmed genomic landscapes, major driver mutations, and…

Continue Reading Prognostic Biomarkers Identified for Pancreatic Ductal Adenocarcinoma Using Whole Genome Sequencing

Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing

Using a temporal multi-omics approach, a team led by scientists from Heidelberg University has identified a protein involved in tumor metastasis that could serve as a new therapeutic cancer target. Metastasis is the leading cause of cancer-related mortality and the mechanistically least well-understood step of the tumor progression cascade. However,…

Continue Reading Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing